Example: A Neuralzeta patient progression over ten years of treatment

Images appear with the consent of the patient
She is an identical triplet who lost her mother and both siblings to ALS/MND within 18 months of onset.
A chart showing her whole family history appears below these images.

Images appearing below: Years 2016,  2020,  2024,  2025 and 2026

Neuralzeta patient 8 years of treatment

The above identical triplet
(Triplet No. 3)
Her family history chart

Her mother and two siblings all died from ALS within 18 months of onset.

It can be seen that after 9 years on Neuralzeta, she continues to be stable and active.

The identical triplets

The triplet on the right takes Neuralzeta and after 9 years is still well and active

Her mother and both her identical sisters died within 18 months of ALS onset

 What happens if Neuralzeta is withdrawn?

Triplet No. 3

.

.

What happens if Neuralzeta is withdrawn?
Neuralzeta patient 8 years of treatment

The independent drug data harvesting platform Patients Like Me (PLM) 2021

The perceived efficacy of Neuralzeta as "Major" is 89%

(Data courtesy of United Healthcare Alliance)

In 2021 the FDA in the US awarded this drug Orphan Drug Designation

Proof of MOA: In Vitro ELISA assay

Important information

Based in Europe, the RC Charity has no connection with any other entity, charity or corporate, and has no external financial support. Being privately funded by a single person and run by a voluntary unpaid trustee, and the public nor any ALS victim have ever been asked for money, there is no requirement to register ​​the charity and incur the associated administrative costs (Registration, trustees, auditing etc.).

The humanitarian objective is to bring a potentially new horizon to those affected by ALS (also known as MND) - irrespective of their financial status. Provided free of any charge on first come first served basis (when funds are available) to any MND/ALS victim who asks for help, only subject to having a credible case history, a confirmed diagnosis, informed patient consent and a valid prescription from a neurologist or medical doctor.

Web sites cost money to optimise. This web site is not intended to be viewed on mobile devices.

As many years are covered in this site, precise data statistics vary at different times. This site is updated occasionally. 2016 ALSTDI page added. 2017 Edavarone comparison page. 2020 Efficacy chart updated, 2021 Family 127 added. 2025 ALSFRS-R added. ​​​ ​​

NOTE: Nothing in this web site may be considered to be medical advice. You must always consult with your neurologist or doctor.

There is another registered domain: www.RCH4als.com, intended to provide information for those diagnosed with ALS/MND and is voluntarily sponsored by PALS around the world treated with RCH4. You may wish to join that group. That web site has no connection with us, however use of the drug name `RCH4` in that domain name is used with the permission of this charity.
Further independent RCH4 patient experience, comment & information is available at Patients Like Me ​

GDPR compliance: In using this site, you agree to us using the standard `cookie` to help us with site management & traffic data. All websites have cookies. However, these do not identify who you are, or exactly where you are. If you do not agree, please leave this site.

Copyright © 2011 - 2026 RC Charity